Decellularized bone marrow extracellular matrix
The invention is directed to compositions comprising decellularized bone marrow extracellular matrix and uses thereof. Methods for repairing or regenerating defective, diseased, damaged or ischemic tissues or organs in a subject, preferably a human, using the decellularized bone marrow extracellular matrix of the invention are also provided. The invention is further directed to a medical device, preferably a stent or an artificial heart, and biocompatible materials, preferably a tissue regeneration scaffold, comprising decellularized bone marrow extracellular matrix for implantation into a subject.
1. A medical device comprising a composition comprising decellularized bone marrow extracellular matrix of an animal, wherein the bone marrow extracellular matrix has been produced in vivo in the animal.
2. The medical device of claim 1 , wherein the non-extracellular matrix component comprises cells, cell components, antigens, cytokines, blood, bone spicules, serum, and fat.
3. The medical device of claim 1 , wherein the animal is a mammal.
4. The medical device of claim 3 , wherein the mammal is selected from the group consisting of a cow, a pig, a horse, a chicken, a cat, a dog, a rat, and a monkey.
5. The medical device of claim 1 , wherein the method further comprises the step of enzymatically treating the decellularized bone marrow extracellular matrix.
6. The medical device of claim 1 , wherein the method further comprises the step of suspending the decellularized bone marrow extracellular matrix in a saline solution.
7. The medical device of claim 1 , wherein the composition further comprises a biological material, wherein the biological material is selected from the group consisting of erythropoietin, stem cell factor (SCF), vascular endothelial growth factor (VEGF), transforming growth factor (TGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), cartilage growth factor (CGF), nerve growth factor (NGF), keratinocyte growth factor (KGF), skeletal growth factor (SGF), osteoblast-derived growth factor (BDGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), cytokine growth factor (CGF), stem cell factor (SCF), platelet-derived growth factor (PDGF), endothelial cell growth supplement (ECGS), colony stimulating factor (CSF), growth differentiation factor (GDF), integrin modulating factor (IMF), calmodulin (CaM), thymidine kinase (TK), tumor necrosis factor (TNF), growth hormone (GH), bone morphogenic proteins (BMP), matrix metalloproteinase (MMP), tissue inhibitor matrix metalloproteinase (TIMP), interferon, interleukins, cytokines, integrin, collagen, elastin, fibrillins, fibronectin, laminin, glycosaminoglycans, hemonectin, thrombospondin, heparan sulfate, dermantan, chondrotin sulfate (CS), hyaluronic acid (HA), vitronectin, proteoglycans, transferrin, cytotactin, tenascin, and lymphokines.
8. The medical device of claim 1 , wherein the composition further comprises a biologically active material.
9. The medical device of claim 8 , wherein the biologically active material is paclitaxel.
10. The medical device of claim 1 , wherein the medical device has a surface and the decellularized bone marrow extracellular matrix is coated onto the surface.
11. The medical device of claim 1 , wherein the medical device comprises a sidewall comprising a wire-like element, wherein the wire-like element comprises the decellularized bone marrow extracellular matrix.
12. The medical device of claim 1 , which is a stent.
13. The medical device of claim 1 , wherein the decellularized bone marrow extracellular matrix is produced by a method comprising the steps of:
a. obtaining from the animal a bone marrow sample having an extracellular matrix and non-extracellular matrix components;
b. processing the bone marrow sample to remove at least some of the non-extracellular matrix components to obtain decellularized bone marrow extracellular matrix; and
c. sterilizing the decellularized bone marrow extracellular matrix.
14. The medical device of claim 13 , wherein at least 50% of the non-extracellular matrix components are removed.
15. The medical device of claim 13 , wherein the bone marrow extracellular matrix is arranged in a structure and wherein the structure is maintained after the bone marrow extracellular matrix is decellularized.
16. A method for treating a defective, diseased, damaged or ischemic tissue or organ in a subject comprising implanting the medical device of claim 1 into the subject.
17. A method for treating a defective, diseased, damaged or ischemic tissue or organ in a subject comprising injecting the medical device of claim 1 into the subject.
18. A method for reconstructing a tissue in a subject comprising implanting the medical device of claim 1 into the subject.
19. A method for reconstructing a tissue in a subject comprising injecting the medical device of claim 1 into the subject.